CN100471840C - 制备罗氟司特的方法 - Google Patents

制备罗氟司特的方法 Download PDF

Info

Publication number
CN100471840C
CN100471840C CNB2004800012164A CN200480001216A CN100471840C CN 100471840 C CN100471840 C CN 100471840C CN B2004800012164 A CNB2004800012164 A CN B2004800012164A CN 200480001216 A CN200480001216 A CN 200480001216A CN 100471840 C CN100471840 C CN 100471840C
Authority
CN
China
Prior art keywords
methoxy
difluoro
amino
dichloropyridine
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004800012164A
Other languages
English (en)
Chinese (zh)
Other versions
CN1701062A (zh
Inventor
B·科尔
B·米勒
W·帕洛施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32981730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100471840(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CN1701062A publication Critical patent/CN1701062A/zh
Application granted granted Critical
Publication of CN100471840C publication Critical patent/CN100471840C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB2004800012164A 2003-03-10 2004-03-08 制备罗氟司特的方法 Expired - Lifetime CN100471840C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03005245 2003-03-10
EP03005245.0 2003-03-10

Publications (2)

Publication Number Publication Date
CN1701062A CN1701062A (zh) 2005-11-23
CN100471840C true CN100471840C (zh) 2009-03-25

Family

ID=32981730

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800012164A Expired - Lifetime CN100471840C (zh) 2003-03-10 2004-03-08 制备罗氟司特的方法

Country Status (29)

Country Link
US (5) US7470791B2 (enExample)
EP (1) EP1606261B1 (enExample)
JP (1) JP4742026B2 (enExample)
KR (1) KR101179012B1 (enExample)
CN (1) CN100471840C (enExample)
AR (1) AR043531A1 (enExample)
AT (1) ATE447555T1 (enExample)
AU (1) AU2004220357B2 (enExample)
BR (1) BRPI0406427B8 (enExample)
CA (1) CA2503290C (enExample)
CY (1) CY1109580T1 (enExample)
DE (1) DE602004023921D1 (enExample)
DK (1) DK1606261T3 (enExample)
EA (1) EA009985B1 (enExample)
ES (1) ES2335498T3 (enExample)
HR (1) HRP20050399B1 (enExample)
IL (1) IL168170A (enExample)
IS (1) IS2723B (enExample)
ME (1) ME00524B (enExample)
MX (1) MXPA04008070A (enExample)
NO (1) NO329301B1 (enExample)
NZ (1) NZ539542A (enExample)
PL (1) PL1606261T3 (enExample)
PT (1) PT1606261E (enExample)
RS (2) RS52908B (enExample)
SI (1) SI1606261T1 (enExample)
TW (1) TWI340741B (enExample)
WO (1) WO2004080967A1 (enExample)
ZA (1) ZA200503191B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN103570610A (zh) * 2012-07-18 2014-02-12 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN104245672A (zh) * 2012-03-07 2014-12-24 神隆医药（常熟）有限公司 制备罗氟司特的新方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
EP1755595A1 (en) * 2004-05-10 2007-02-28 Altana Pharma AG Use of roflumilast for the prophylaxis or treatment of emphysema
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
CN102311382B (zh) * 2010-06-29 2014-05-21 大道隆达（北京）医药科技发展有限公司 罗氟司特的晶态及其制备方法
WO2012147098A2 (en) * 2011-04-28 2012-11-01 Glenmark Generics Limited Novel process for the preparation of 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) benzamide
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN102336703B (zh) * 2011-07-20 2013-09-25 华润赛科药业有限责任公司 一种制备罗氟司特的方法
CN102351787B (zh) * 2011-08-18 2014-08-13 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特化合物
CN103012255B (zh) * 2011-09-21 2014-06-11 天津康鸿医药科技发展有限公司 罗氟司特晶型化合物、其制备方法、组合物及应用
CN102336704B (zh) * 2011-10-19 2013-04-17 丁克 一种制备罗氟司特的方法
CN102336705B (zh) * 2011-10-28 2013-03-27 成都苑东药业有限公司 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
CN102603623A (zh) * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
CN102617340B (zh) * 2012-03-05 2014-03-26 山西仟源制药股份有限公司 制备3-环丙基甲氧基-4-二氟甲氧基苯甲酸的方法
WO2013131255A1 (en) * 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
EP2909177B1 (en) 2012-10-17 2017-03-29 Interquim, S.A. Process for preparing roflumilast
CN103319333B (zh) * 2013-07-15 2014-12-10 天津南开允公医药科技有限公司 一种制备3-环丙基甲氧基-4-二氟甲氧基苯甲酰氯化合物的方法
AU2014307802A1 (en) * 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with combination therapy
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
CN104892500A (zh) * 2015-05-18 2015-09-09 武汉利宝瑞医药科技有限公司 罗氟司特的合成工艺
JP6727302B2 (ja) * 2016-07-01 2020-07-22 久光製薬株式会社 Ｎ−（３，５−ジクロロピリド−４−イル）−ｎ−メチル−３−シクロプロピルメトキシ−４−ジフルオロメトキシベンズアミドの製造方法
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
KR20230146513A (ko) 2020-12-04 2023-10-19 아큐티스 바이오테라퓨틱스, 인크. 항진균 특성을 갖는 국소 로플루밀라스트 제형
SI4175619T1 (sl) 2021-07-09 2024-08-30 Astrazeneca Pharmaceuticals Lp Sestavki, postopki in sistemi za aerosolno dostavo zdravila
US20250057764A1 (en) 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025517A1 (en) * 1992-06-15 1993-12-23 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
WO1995001338A1 (de) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4024240A (en) 1975-07-18 1977-05-17 Eli Lilly And Company Antibiotic A-32390 compositions
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
NZ196700A (en) 1980-04-18 1983-04-12 Smith & Nephew Ass Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives
EP0068378B1 (en) 1981-06-26 1986-03-05 Schering Corporation Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
GB8415540D0 (en) 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS625966A (ja) 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (en) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5286494A (en) 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4791117A (en) 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
DE3855692D1 (de) 1987-07-16 1997-01-16 Byk Gulden Lomberg Chem Fab Imidazo[1,2-a]pyridine
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US4900775A (en) 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5011843A (en) 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
CA2011086A1 (en) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3943385A1 (de) 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
FR2657257B1 (fr) 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
AU634880B2 (en) 1990-03-28 1993-03-04 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative, antiulcer drug containing the same, and production of said derivative
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
WO1992021328A1 (en) 1991-05-28 1992-12-10 Affinity Biotech, Inc. Chewable drug-delivery composition
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
DE59209687D1 (de) 1991-10-25 1999-06-02 Byk Gulden Lomberg Chem Fab Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
US5262171A (en) 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
DE69222182T2 (de) 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
DE69333688T2 (de) 1992-07-28 2005-11-03 Aventis Pharma Ltd., West Malling Inhibitoren von c-amp phosphodiesterase
US5891904A (en) 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5824687A (en) 1993-04-22 1998-10-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridinium salts and their use for the control of helicobacter bacteria
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (uk) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
WO1996003405A1 (de) 1994-07-28 1996-02-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridin-azolidinone
JP3031280B2 (ja) 1994-08-19 2000-04-10 東陶機器株式会社 便器洗浄装置
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
FR2746800B1 (fr) 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
CA2276429C (en) 1997-02-17 2007-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
US6624181B1 (en) 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
IL132608A0 (en) 1997-05-28 2001-03-19 Byk Gulden Lomberg Chem Fab Fused dihydropyran compounds medicaments containing the same and the use thereof
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
WO1999029299A1 (en) 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel suppository form comprising an acid-labile active compound
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
CN1306438A (zh) 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802794D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
HUP0103160A3 (en) 1998-08-26 2002-11-28 Smithkline Beecham Corp Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor
CZ292335B6 (cs) 1998-09-23 2003-09-17 Altana Pharma Ag Tetrahydropyridoethery, jejich použití a farmaceutický prostředek
TR200100893T2 (tr) 1998-09-29 2001-11-21 Fujisawa Pharmaceutical Co., Ltd. Piridopirazin bileşiğinin yeni tuzları ve bunların kristalleri
WO2000020033A1 (en) 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
US20020006418A1 (en) 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
EP1127059B1 (en) 1998-11-03 2008-02-20 Nycomed GmbH Imidazonaphthyridines
US6417190B1 (en) 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
DE60015098T2 (de) 1999-03-10 2006-02-02 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
CN1126468C (zh) 1999-04-08 2003-11-05 王力田 一种黑玉米秸秆饮料及其制备方法
US6503923B1 (en) 1999-04-17 2003-01-07 Altana Pharma Ag Haloalkoxy imidazonaphthyridines
KR100328972B1 (ko) 1999-04-23 2002-03-20 서경배 피부 유용 활성성분을 함유한 화장료 또는 피부도포용 의약품 조성물의 제조방법 및 이러한 방법에 의해 제조된 화장료 또는 피부도포용 의약품 조성물
AU4558800A (en) 1999-05-04 2000-11-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination comprising roflumilast and a pde-3 inhibitor
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
PL352882A1 (en) 1999-06-07 2003-09-22 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound
HK1044277B (en) 1999-08-03 2014-02-28 Icos Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
KR100729836B1 (ko) 1999-10-25 2007-06-18 소니 가부시끼 가이샤 콘텐츠 데이터 관리방법
CA2389293A1 (en) 1999-10-29 2001-05-10 Smithkline Beecham Corporation Method for administering a phosphodiesterase 4 inhibitor
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6379682B1 (en) 2000-02-07 2002-04-30 Color Access, Inc. Clear water-in-oil emulsions
US20030207845A1 (en) 2001-02-08 2003-11-06 Keating Elizabeth T. Method and compositions for treating an inflammatory disease
JP2004500404A (ja) 2000-03-27 2004-01-08 カール　−　ツァイス　−　シュティフツング 生物活性ガラスを含む新規化粧品、ボディケア、洗浄剤および栄養サプリメント組成物および製造方法およびその使用
CA2407780A1 (en) 2000-05-25 2001-11-29 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
EP1161950A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
ATE529097T1 (de) 2000-12-07 2011-11-15 Nycomed Gmbh Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
ES2403238T3 (es) 2000-12-07 2013-05-16 Takeda Gmbh Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
PT1341528E (pt) 2000-12-07 2012-03-20 Nycomed Gmbh Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
NZ527585A (en) 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
WO2002069939A2 (en) 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
FR2821745B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6702796B2 (en) 2001-03-26 2004-03-09 The Procter & Gamble Company Absorbent interlabial device having an improved tab
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK1511481T3 (da) 2002-05-28 2011-01-24 Nycomed Gmbh Ophthalmologisk anvendelse af roflumilast til behandling af øjensygdomme
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20040136991A1 (en) 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of anemia using TNFalpha inhibitors
US20030018071A1 (en) 2002-08-09 2003-01-23 Rennard Stephen I. Method and compositions for treating fibrotic diseases
BR0313330A (pt) 2002-08-10 2005-06-14 Altana Pharma Ag Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
CA2495827C (en) 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
CA2497176A1 (en) 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
US20060199865A1 (en) 2002-11-27 2006-09-07 Rolf Beume Synergistic combination comprising roflumilast and (r,r) - formoterol
DK1567139T3 (da) 2002-11-27 2008-11-03 Nycomed Gmbh Hidtil ukendt synergistisk kombination der omfatter roflumilast og formoterol
WO2004052345A1 (en) 2002-12-11 2004-06-24 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
ATE444731T1 (de) 2003-01-30 2009-10-15 Ethypharm Sa Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
ES2300755T3 (es) 2003-03-28 2008-06-16 Nycomed Gmbh Combinacion sinergica que comprende roflumilast y un agente anticolinergico seleccionado de sales de tiotropio para el tratamiento de enfermedades respiratorias.
CN1791429A (zh) 2003-05-22 2006-06-21 奥坦纳医药公司 包含pde4抑制剂和pde5抑制剂的组合物
US20050026883A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2007501810A (ja) 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
BRPI0413881A (pt) 2003-08-28 2006-10-24 Sandoz Ag composição farmacêutica compreendendo anticonvulsivante com revestimento de mascaramento de gosto
WO2005026095A1 (en) 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
EP1677778A2 (en) 2003-10-09 2006-07-12 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
CA2542277A1 (en) 2003-10-21 2005-05-12 Pharmacia Corporation Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
EP1755595A1 (en) 2004-05-10 2007-02-28 Altana Pharma AG Use of roflumilast for the prophylaxis or treatment of emphysema
AU2005272647A1 (en) 2004-08-12 2006-02-23 Sicor, Inc. Process for the preparation of 3-oximino steroids
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006094640A2 (en) 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
WO2008006051A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
USD580547S1 (en) 2007-07-31 2008-11-11 Nycomed Gmbh Tablet
JP2009167052A (ja) 2008-01-16 2009-07-30 Kyocera Corp 単結晶シリコン粒子の製造方法
JP5271070B2 (ja) 2008-12-24 2013-08-21 エスアイアイ・プリンテック株式会社 ヘッドチップ、液体噴射ヘッド及び液体噴射装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025517A1 (en) * 1992-06-15 1993-12-23 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
WO1995001338A1 (de) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Process Development of the PDE IV Inhibitor3-(cyclopentyloxy)-N-(3,5-dichloropyrid-4-yl)-4-methoxybenzamide. David C. Cook, et al.Organic Process Research & Development,Vol.2 No.3. 1998 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN104245672A (zh) * 2012-03-07 2014-12-24 神隆医药（常熟）有限公司 制备罗氟司特的新方法
CN104245672B (zh) * 2012-03-07 2016-05-18 神隆医药（常熟）有限公司 制备罗氟司特的方法
CN103570610A (zh) * 2012-07-18 2014-02-12 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法

Also Published As

Publication number Publication date
RS52908B (sr) 2014-02-28
ATE447555T1 (de) 2009-11-15
US8618142B2 (en) 2013-12-31
CA2503290C (en) 2012-12-04
KR101179012B1 (ko) 2012-09-03
TW200508201A (en) 2005-03-01
IL168170A (en) 2010-12-30
AR043531A1 (es) 2005-08-03
HRP20050399B1 (hr) 2013-09-30
ES2335498T3 (es) 2010-03-29
BRPI0406427A (pt) 2005-10-04
JP2006519818A (ja) 2006-08-31
EA009985B1 (ru) 2008-04-28
DK1606261T3 (da) 2010-01-18
CY1109580T1 (el) 2014-08-13
NO329301B1 (no) 2010-09-27
TWI340741B (en) 2011-04-21
JP4742026B2 (ja) 2011-08-10
US20120294942A1 (en) 2012-11-22
RS20050669A (sr) 2008-04-04
US7470791B2 (en) 2008-12-30
HK1085480A1 (zh) 2006-08-25
NO20051957L (no) 2005-10-06
KR20050106392A (ko) 2005-11-09
PL1606261T3 (pl) 2010-04-30
DE602004023921D1 (de) 2009-12-17
AU2004220357A1 (en) 2004-09-23
NZ539542A (en) 2007-09-28
CN1701062A (zh) 2005-11-23
AU2004220357B2 (en) 2010-09-30
US20060004061A1 (en) 2006-01-05
EP1606261A1 (en) 2005-12-21
MXPA04008070A (es) 2004-11-26
US8536206B2 (en) 2013-09-17
EP1606261B1 (en) 2009-11-04
SI1606261T1 (sl) 2010-03-31
ME00524B (me) 2011-10-10
US8604064B2 (en) 2013-12-10
CA2503290A1 (en) 2004-09-23
NO20051957D0 (no) 2005-04-21
BRPI0406427B1 (pt) 2019-05-14
EA200501350A1 (ru) 2006-04-28
WO2004080967A1 (en) 2004-09-23
PT1606261E (pt) 2010-01-11
IS7810A (is) 2005-04-19
HRP20050399A2 (en) 2006-08-31
US20090171096A1 (en) 2009-07-02
US20130224299A1 (en) 2013-08-29
IS2723B (is) 2011-03-15
US20130231374A1 (en) 2013-09-05
BRPI0406427B8 (pt) 2021-05-25
ZA200503191B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
CN100471840C (zh) 制备罗氟司特的方法
CN102317262B (zh) 苯甲酸(1-苯基-2-吡啶基-4-基)乙酯作为磷酸二酯酶抑制剂
US7671066B2 (en) Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
US8203000B2 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
ES2401052T3 (es) Derivados éster como inhibidores de fosfodiesterasa
US20130324501A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
ES2219395T3 (es) Sal anhidra.
HK1085480B (en) Process for the preparation of roflumilast
HK1162508B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085480

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1085480

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: NYCOMED INC.

Free format text: FORMER NAME: NYCOMED GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: NYCOMED GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED INC.

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

ASS Succession or assignment of patent right

Owner name: NYCOMED GERMANY HOLDING GMBH

Free format text: FORMER OWNER: NYCOMED ASSET MANAGEMENT GMBH

Effective date: 20150619

Owner name: NYCOMED ASSET MANAGEMENT GMBH

Free format text: FORMER OWNER: TAKEDA GMBH

Effective date: 20150619

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED GERMANY HOLDING GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed Germany holding LLC

TR01 Transfer of patent right

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed Germany holding LLC

Address before: Konstanz

Patentee before: Nycomed asset management LLC

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed asset management LLC

Address before: Konstanz

Patentee before: TAKEDA GmbH

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20170105

Address after: Swedish Suo de Jie

Patentee after: ASTRAZENECA AB

Address before: Konstanz

Patentee before: TAKEDA GmbH

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20090325